Ofatumumab, High Dose Methylprednisolone, Ofatumumab and Lenalidomide Consolidative Therapy for Untreated CLL/SLL
Phase 2 Completed
45 enrolled 12 charts
Ofatumumab With or Without Bendamustine for Patients With Mantle Cell Lymphoma Ineligible for Autologous Stem Cell Transplant
Phase 2 Completed
30 enrolled 15 charts
Ofatumumab & Ibrutinib + Allogeneic Bone Marrow Transplant or Consolidation in High Risk Chronic Lymphocytic Leukemia
Phase 2 Completed
19 enrolled
Ofatumumab for High-Risk Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Phase 2 Completed
44 enrolled 7 charts
Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagnosed or Relapsed or Refractory Burkitt Lymphoma or Relapsed or Refractory Acute Lymphoblastic Leukemia
Phase 2 Completed
14 enrolled 10 charts
Ofatumumab in Combination With Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine Sulfate, and Dexamethasone Alternating With Ofatumumab in Combination With Cytarabine and Methotrexate in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Phase 2 Completed
37 enrolled 19 charts
Ofatumumab-based Induction Chemoimmunotherapy in Previously Untreated Patients With CLL/SLL
Phase 2 Completed
32 enrolled 16 charts
versus
Phase 2 Completed
34 enrolled 11 charts
FIL_MIRO
Phase 2 Completed
110 enrolled
PLRG8
Phase 2 Completed
77 enrolled
Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Phase 2 Completed
51 enrolled 7 charts
Ofatumumab as Front-Line Therapy in Treating Elderly Participants With Chronic Lymphocytic Leukemia
Phase 2 Completed
34 enrolled 9 charts
Study of OFATUMUMAB as Part of the Scheme of Reduced Intensity Conditioning in High Risk Non-Hodgkin Lymphoma B Patients
Phase 2 Completed
33 enrolled
Combination Chemotherapy and Ofatumumab in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
Phase 2 Completed
72 enrolled 10 charts
Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)
Phase 2 Completed
29 enrolled 9 charts
Chemotherapy Plus Ofatumumab Followed by G-CSF for Mobilization of Peripheral Blood Stem Cells in Patients With Non-Hodgkin's Lymphomas
Phase 2 Completed
50 enrolled 7 charts
Sequential Regimen of Bendamustin-Debulking Followed by Ofatumumab and Ibrutinib in CLL Patients (CLL2-BIO)
Phase 2 Completed
66 enrolled
An Open-Label Phase 2 Study of Ofatumumab (Arzerra) in Combination With Oral GSK2110183 in the Treatment of Relapsed and Refractory Chronic Lymphocytic Leukemia (CLL)
Phase 2 Completed
28 enrolled 12 charts
Lenalidomide and Ofatumumab in Treating Participants With Previously Treated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
36 enrolled 7 charts
Ofatumumab, Pentostatin, and Cyclophosphamide in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
82 enrolled 10 charts
Ofatumumab and Bendamustine Followed by Maintenance Ofatumumab for Rituximab Relapsed Indolent B-cell Non-Hodgkin's Lymphoma (B-NHL)
Phase 2 Completed
49 enrolled 13 charts
CRC027
Phase 2 Completed
21 enrolled 12 charts
CHOP-OR
Phase 2 Completed
43 enrolled
Study of Bendamustine and Ofatumumab in Elderly Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma Who Are Poor Candidates for R-CHOP Chemotherapy
Phase 2 Completed
22 enrolled 14 charts
Rapid Infusion of Ofatumumab in Patients With Previously Treated Chronic Lymphocytic Leukemia
Phase 2 Completed
34 enrolled 10 charts
A Phase II Trial of Ofatumumab in Subjects With Waldenstrom's Macroglobulinemia
Phase 2 Completed
37 enrolled 25 charts
A Phase I/II, a Single Arm, Open-label Study of Ofatumumab (GSK1841157) in Patients With Previously Treated Chronic Lymphocytic Leukemia
Phase 2 Completed
10 enrolled 35 charts
Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Phase 2 Completed
99 enrolled 27 charts
Ofatumumab for Patients With Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Phase 2 Completed
77 enrolled 9 charts
Ofatumumab Induction and Maintenance in Elderly Patients With Poor Risk CLL in the Context of Allogeneic Transplantation
Phase 2 Completed
20 enrolled
DLBL
Phase 2 Completed
17 enrolled
Study of Ofatumumab and ESHAP for the Treatment of Hodgkin's Lymphoma
Phase 2 Completed
64 enrolled
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma
Phase 2 Completed
10 enrolled
A Phase I/II, Open-label Study of Ofatumumab Added to Chlorambucil in Previously Untreated Japanese Patients With Chronic Lymphocytic Leukemia
Phase 2 Completed
10 enrolled 52 charts
Ofatumumab in Patients With Relapsed/Progressive Diffused Large B-Cell Lymphoma (DLBCL) Ineligible for or Relapse/Progression After Transplant
Phase 2 Completed
81 enrolled 18 charts
Ofatumumab Added to Dexamethasone in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia
Phase 2 Completed
33 enrolled
MUNIN
Phase 2 Completed
59 enrolled 21 charts
HuMax-CD20 in B-Cell Chronic Lymphocytic Leukemia (B-CLL) Patients Failing Fludarabine and Alemtuzumab
Phase 2 Completed
223 enrolled 31 charts
BIFROST
Phase 2 Completed
61 enrolled 22 charts
Phase II Study of Ofatumumab Plus Ifosfamide, Carboplatin, Etoposide (ICE) or Dexamethasone, Cytarabine, Cisplatin (DHAP) Chemotherapy Regimen in Relapsed/ Refractory Diffuse Large B Cell Lymphoma (DLBCL)
Phase 2 Completed
61 enrolled 25 charts
Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)
Phase 2 Completed
50 enrolled 10 charts